70.20 0.00 (0.00%)
After hours: 4:23PM EST
|Bid||68.50 x 100|
|Ask||74.00 x 1000|
|Day's Range||69.79 - 70.25|
|52 Week Range||45.47 - 70.25|
|PE Ratio (TTM)||37.58|
|Earnings Date||Feb 1, 2018|
|Forward Dividend & Yield||0.64 (0.91%)|
|1y Target Est||71.80|
Baxter International Inc. , a global leader in sterile medication production and delivery, today announced the U.S. Food and Drug Administration approval of Bivalirudin in 0.9 percent Sodium Chloride Injection .
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BAX. BAX credit default swap spreads are within the middle of their range for the last three years.
Baxter International Inc. will present at the 7th Annual Leerink Partners Global Healthcare Conference on Wednesday, February 14, 2018, in New York. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 11:30 a.m.
Baxter's (BAX) Arisure Closed System reduces exposure risk of healthcare professionals to needles. Also, the latest development promotes safe handling of hazardous drugs.
In 3Q17, Bioverativ’s (BIVV) drug Alprolix generated revenue of $88.5 million, which reflected a rise of ~4% on a year-over-year (or YoY) basis. In 3Q17, Alprolix contributed ~32.2% of Bioverativ’s net product sales. Alprolix reported revenue of $264.2 million in the first nine months of 2017 (which ended in September 2017) compared to its revenue of $240.5 million in the first nine months of 2016.
Baxter International Inc. , a leader in innovative technology for medication delivery, today announced a distribution agreement for the U.S. launch of the Arisure Closed System Transfer device, which consists of several components that work together to help prevent contaminants from entering the intravenous medication delivery system and the escape of hazardous substances out of the system during drug ...
Stock Monitor: Mallinckrodt Post Earnings Reporting LONDON, UK / ACCESSWIRE / January 10, 2018 / Active-Investors.com has just released a free research report on Baxter International Inc. (NYSE: BAX ). ...
Baxter International , will host a conference call to discuss its fourth quarter 2017 financial results on Thursday, February 1, 2018, at 7:30 a.m. Central Standard Time.
Mallinckrodt's (MNK) strategy to streamline its business to evolve as a top-performing specialty pharmaceutical company has led the company to enter into an agreement to sell Recothrom and Preveleak to Baxter.
STAINES-UPON-THAMES, United Kingdom, Jan. 8, 2018 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading specialty pharmaceutical company, announced today it has entered into an agreement under which it will sell certain hemostasis products to Baxter International Inc. (BAX) for approximately $185 million, with upfront payment of $153 million, inclusive of existing inventory, and the remainder in potential future milestones. RECOTHROM® Thrombin topical (Recombinant) and PREVELEAK® Surgical Sealant, both products for use in the control of bleeding in the surgical suite, are included in the transaction, as well as the manufacturing operation for PREVELEAK. The products will complement and broaden Baxter's current portfolio of hemostats and sealants, offering surgeons additional products to address patients' varying needs.
Baxter International Inc. , a global medical products company, is committed to advancing surgical innovation and today announced an agreement to acquire two hemostat and sealant products from Mallinckrodt plc: RECOTHROM Thrombin topical , the first and only stand-alone recombinant thrombin, and PREVELEAK Surgical Sealant, which is used in vascular reconstruction.
The U.S. is facing a nationwide shortage of intravenous bags because of production woes linked to the Puerto Rico hurricane, forcing many hospitals to use more time-consuming ways to administer drugs.
Baxter International Inc (NYSE:BAX) generated a below-average return on equity of 11.31% in the past 12 months, while its industry returned 13.25%. An investor may attribute an inferior ROE toRead More...